Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage) for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Sponsor: Agenus Inc.
Terminated
Sponsor's business decision
Other terminated trials from Agenus Inc.
- Gliosarcoma · Phase PHASE2 · May 2023
- Advanced Solid Tumor · Phase PHASE1 · Sep 2021
- Advanced Cancer · Phase PHASE1 · Dec 2019
- NSCLC Stage IV · Phase PHASE2 · Mar 2019
- Leukemia, Myeloid, Chronic · Phase PHASE2 · Apr 2006
More terminations from Agenus Inc.
This PHASE2 trial investigates Renal Cell Carcinoma and is currently terminated or withdrawn. Agenus Inc. leads this study, which shows 10 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agenus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .